$RKDA
Arcadia Biosciences, Inc.

2024 Q2 Form 10-Q Financial Statement

#000095017024058563 Filed on May 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $1.306M $1.255M
YoY Change -5.98% -16.83%
Cost Of Revenue $633.0K $820.0K
YoY Change -35.47% -0.61%
Gross Profit $673.0K $435.0K
YoY Change 64.95% -36.4%
Gross Profit Margin 51.53% 34.66%
Selling, General & Admin $2.683M $3.189M
YoY Change -29.67% -27.39%
% of Gross Profit 398.66% 733.1%
Research & Development $10.00K $272.0K
YoY Change -97.44% -24.23%
% of Gross Profit 1.49% 62.53%
Depreciation & Amortization $17.00K $51.00K
YoY Change -74.63% -28.17%
% of Gross Profit 2.53% 11.72%
Operating Expenses $2.693M $3.461M
YoY Change -35.97% -27.15%
Operating Profit $1.980M -$3.064M
YoY Change -152.23% -24.31%
Interest Expense -$280.0K $638.0K
YoY Change -106.06% -43.94%
% of Operating Profit -14.14%
Other Income/Expense, Net $150.0K $3.000K
YoY Change -1253.85% -90.63%
Pretax Income $1.850M -$2.423M
YoY Change 125.89% -74.18%
Income Tax $0.00
% Of Pretax Income 0.0%
Net Earnings $1.061M -$2.423M
YoY Change 28.92% -74.18%
Net Earnings / Revenue 81.24% -193.07%
Basic Earnings Per Share $0.78 -$1.78
Diluted Earnings Per Share $0.78 -$1.78
COMMON SHARES
Basic Shares Outstanding 1.363M 1.363M
Diluted Shares Outstanding 1.363M 1.362M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.108M $8.501M
YoY Change -56.19% -63.04%
Cash & Equivalents $5.500M $3.300M
Short-Term Investments $2.604M $5.184M
Other Short-Term Assets $749.0K $550.0K
YoY Change -27.84% -20.63%
Inventory $978.0K $1.831M
Prepaid Expenses
Receivables $840.0K $760.0K
Other Receivables $1.759M $0.00
Total Short-Term Assets $12.43M $11.64M
YoY Change -46.72% -57.21%
LONG-TERM ASSETS
Property, Plant & Equipment $54.00K $328.0K
YoY Change -90.36% -47.27%
Goodwill
YoY Change
Intangibles $39.00K $39.00K
YoY Change -2.5% -2.5%
Long-Term Investments
YoY Change
Other Assets $164.0K $164.0K
YoY Change -7.87% -0.61%
Total Long-Term Assets $4.935M $4.404M
YoY Change 42.67% 37.41%
TOTAL ASSETS
Total Short-Term Assets $12.43M $11.64M
Total Long-Term Assets $4.935M $4.404M
Total Assets $17.37M $16.05M
YoY Change -35.19% -47.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.640M $1.807M
YoY Change -41.76% -35.46%
Accrued Expenses $563.0K $801.0K
YoY Change -43.3% -21.01%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change
Total Short-Term Liabilities $2.698M $2.878M
YoY Change -34.05% -29.75%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.000M $2.000M
YoY Change 0.0% 0.0%
Total Long-Term Liabilities $2.000M $2.000M
YoY Change 0.0% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.698M $2.878M
Total Long-Term Liabilities $2.000M $2.000M
Total Liabilities $5.803M $5.563M
YoY Change -36.01% -59.45%
SHAREHOLDERS EQUITY
Retained Earnings -$273.2M -$274.3M
YoY Change 2.55% 2.66%
Common Stock $284.8M $284.7M
YoY Change 0.2% 0.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.70M $10.62M
YoY Change
Total Liabilities & Shareholders Equity $17.37M $16.05M
YoY Change -35.19% -47.23%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income $1.061M -$2.423M
YoY Change 28.92% -74.18%
Depreciation, Depletion And Amortization $17.00K $51.00K
YoY Change -74.63% -28.17%
Cash From Operating Activities -$2.456M -$3.200M
YoY Change -48.81% -8.57%
INVESTING ACTIVITIES
Capital Expenditures $3.000K $13.00K
YoY Change -40.0%
Acquisitions
YoY Change
Other Investing Activities $4.646M $17.00K
YoY Change -198.62% -94.6%
Cash From Investing Activities $4.643M $4.000K
YoY Change -198.45% -98.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 5.000K
YoY Change -99.91%
NET CHANGE
Cash From Operating Activities -2.456M -3.200M
Cash From Investing Activities 4.643M 4.000K
Cash From Financing Activities 0.000 5.000K
Net Change In Cash 2.187M -3.201M
YoY Change -122.99% -235.98%
FREE CASH FLOW
Cash From Operating Activities -$2.456M -$3.200M
Capital Expenditures $3.000K $13.00K
Free Cash Flow -$2.459M -$3.213M
YoY Change -48.8% -8.2%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001469443
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-37383
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
Arcadia Biosciences, Inc.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-0571538
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
5950 Sherry Lane
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 215
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Dallas
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
75225
CY2024Q1 dei City Area Code
CityAreaCode
214
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
974-8921
CY2024Q1 dei Security12b Title
Security12bTitle
Common
CY2024Q1 dei Trading Symbol
TradingSymbol
RKDA
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1362840
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3317000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6518000
CY2024Q1 us-gaap Short Term Investments
ShortTermInvestments
5184000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
5124000
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2024Q1 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
760000
CY2023Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
514000
CY2024Q1 us-gaap Inventory Net
InventoryNet
1831000
CY2023Q4 us-gaap Inventory Net
InventoryNet
1958000
CY2024Q1 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
15000
CY2023Q4 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
51000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
535000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
807000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
11642000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
14972000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
328000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
384000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
695000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
792000
CY2024Q1 us-gaap Inventory Noncurrent
InventoryNoncurrent
3178000
CY2023Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
3354000
CY2024Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
39000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
39000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4071000
CY2024Q1 us-gaap Costs And Expenses
CostsAndExpenses
4319000
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
5099000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3064000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3867000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
164000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
164000
CY2024Q1 us-gaap Assets
Assets
16046000
CY2023Q4 us-gaap Assets
Assets
19705000
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1732000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2410000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
801000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
852000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2878000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3590000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
155000
CY2024Q1 rkda Common Stock Warrant And Option Liabilities
CommonStockWarrantAndOptionLiabilities
664000
CY2023Q4 rkda Common Stock Warrant And Option Liabilities
CommonStockWarrantAndOptionLiabilities
1257000
CY2024Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2000000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2000000
CY2024Q1 us-gaap Liabilities
Liabilities
5563000
CY2023Q4 us-gaap Liabilities
Liabilities
7002000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1362840
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1362840
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1285337
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1285337
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
65000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
65000
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
284658000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
284515000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
161000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
101000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-274263000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-271840000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
10621000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
12841000
CY2024Q1 us-gaap Minority Interest
MinorityInterest
-138000
CY2023Q4 us-gaap Minority Interest
MinorityInterest
-138000
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10483000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
12703000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16046000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19705000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1255000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1232000
CY2024Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
820000
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
688000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
272000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
359000
CY2024Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-2000
CY2023Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
19000
CY2024Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
36000
CY2023Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3189000
CY2024Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
45000
CY2023Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
198000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
32000
CY2024Q1 rkda Gain Loss On Private Placement
GainLossOnPrivatePlacement
0
CY2023Q1 rkda Gain Loss On Private Placement
GainLossOnPrivatePlacement
-6076000
CY2024Q1 rkda Change In Fair Value Of Common Stock Warrant And Option Liabilities
ChangeInFairValueOfCommonStockWarrantAndOptionLiabilities
593000
CY2023Q1 rkda Change In Fair Value Of Common Stock Warrant And Option Liabilities
ChangeInFairValueOfCommonStockWarrantAndOptionLiabilities
940000
CY2024Q1 rkda Issuance And Offering Costs Allocated To Liability Classified Options
IssuanceAndOfferingCostsAllocatedToLiabilityClassifiedOptions
0
CY2023Q1 rkda Issuance And Offering Costs Allocated To Liability Classified Options
IssuanceAndOfferingCostsAllocatedToLiabilityClassifiedOptions
430000
CY2024Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-2423000
CY2023Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-9203000
CY2024Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
0
CY2023Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-181000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2423000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9384000
CY2024Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.78
CY2024Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.78
CY2023Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-10.65
CY2023Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-10.65
CY2024Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
CY2024Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0
CY2023Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.21
CY2023Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.21
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.78
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.78
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.86
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-10.86
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1361657
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1361657
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
864391
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
864391
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
60000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
60000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2363000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9384000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
12703000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
5000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
138000
CY2024Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
60000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-2423000
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10483000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
20900000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
5000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
212000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-9384000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
16692000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-2423000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-9384000
CY2024Q1 rkda Change In Fair Value Of Common Stock Warrant And Option Liabilities
ChangeInFairValueOfCommonStockWarrantAndOptionLiabilities
593000
CY2023Q1 rkda Change In Fair Value Of Common Stock Warrant And Option Liabilities
ChangeInFairValueOfCommonStockWarrantAndOptionLiabilities
940000
CY2024Q1 rkda Issuance And Offering Costs Allocated To Liability Classified Options
IssuanceAndOfferingCostsAllocatedToLiabilityClassifiedOptions
0
CY2023Q1 rkda Issuance And Offering Costs Allocated To Liability Classified Options
IssuanceAndOfferingCostsAllocatedToLiabilityClassifiedOptions
430000
CY2024Q1 rkda Gain Loss On Private Placement
GainLossOnPrivatePlacement
-0
CY2023Q1 rkda Gain Loss On Private Placement
GainLossOnPrivatePlacement
-6076000
CY2024Q1 us-gaap Depreciation
Depreciation
51000
CY2023Q1 us-gaap Depreciation
Depreciation
71000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
177000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
180000
CY2024Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-2000
CY2023Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
19000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
138000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
212000
CY2024Q1 us-gaap Inventory Write Down
InventoryWriteDown
0
CY2023Q1 us-gaap Inventory Write Down
InventoryWriteDown
23000
CY2024Q1 rkda Disposal Group Including Discontinued Operation Impairment Of Property And Equipment
DisposalGroupIncludingDiscontinuedOperationImpairmentOfPropertyAndEquipment
36000
CY2023Q1 rkda Disposal Group Including Discontinued Operation Impairment Of Property And Equipment
DisposalGroupIncludingDiscontinuedOperationImpairmentOfPropertyAndEquipment
0
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
246000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-80000
CY2024Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-303000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
37000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-275000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-203000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-678000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-149000
CY2024Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
17000
CY2023Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-33000
CY2024Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
0
CY2023Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
12000
CY2024Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-269000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-191000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3210000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3466000
CY2024Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
17000
CY2023Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
30000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
CY2024Q1 us-gaap Proceeds From Sale Of Equity Method Investments
ProceedsFromSaleOfEquityMethodInvestments
0
CY2023Q1 us-gaap Proceeds From Sale Of Equity Method Investments
ProceedsFromSaleOfEquityMethodInvestments
285000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
315000
CY2024Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
5000
CY2023Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
5000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5505000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3201000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2354000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6518000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
20644000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3317000
CY2023Q4 rkda Inventory Finished Goods Current And Non Current
InventoryFinishedGoodsCurrentAndNonCurrent
4773000
CY2024Q1 rkda Inventory Current And Non Current Net
InventoryCurrentAndNonCurrentNet
5009000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22998000
CY2024Q1 rkda Proceeds From Sale Of Property And Equipment In Accounts Receivable And Other Receivables
ProceedsFromSaleOfPropertyAndEquipmentInAccountsReceivableAndOtherReceivables
12000
CY2023Q1 rkda Proceeds From Sale Of Property And Equipment In Accounts Receivable And Other Receivables
ProceedsFromSaleOfPropertyAndEquipmentInAccountsReceivableAndOtherReceivables
0
CY2024Q1 rkda Purchases Of Property And Equipment In Accounts Payable And Accrued Expenses
PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses
13000
CY2023Q1 rkda Purchases Of Property And Equipment In Accounts Payable And Accrued Expenses
PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses
0
CY2024Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
86000
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2024Q1 rkda Proceeds From Sale Of Equity Method Investments In Accounts And Other Receivable
ProceedsFromSaleOfEquityMethodInvestmentsInAccountsAndOtherReceivable
0
CY2023Q1 rkda Proceeds From Sale Of Equity Method Investments In Accounts And Other Receivable
ProceedsFromSaleOfEquityMethodInvestmentsInAccountsAndOtherReceivable
285000
CY2024Q1 rkda Entity Place Of Incorporation
EntityPlaceOfIncorporation
Arizona
CY2024Q1 rkda Entity Incorporation Year Of Incorporation
EntityIncorporationYearOfIncorporation
2002
CY2024Q1 rkda Entity Reincorporation State Country Name
EntityReincorporationStateCountryName
Delaware
CY2024Q1 rkda Entity Reincorporation Date Of Reincorporation
EntityReincorporationDateOfReincorporation
2015-03
CY2024Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reclassifications</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain previously reported financial information has been reclassified to conform to the current year presentation. For a discussion of the reclassification of the financial presentation of our former body care brands reported as discontinued operations, see “Discontinued Operations” section below. Unless otherwise noted, amounts and disclosures throughout these notes to condensed consolidated financial statements relate solely to continuing operations and exclude all discontinued operations.</span></p>
CY2024Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
In February 2023, the Company’s board of directors approved a reverse split of 40:1 on the Company’s issued and outstanding common stock.
CY2024Q1 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
19118
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-274300000
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3300000
CY2024Q1 us-gaap Short Term Investments
ShortTermInvestments
5200000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-2400000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3200000
CY2023 us-gaap Profit Loss
ProfitLoss
-14000000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
15300000
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3300000
CY2024Q1 us-gaap Short Term Investments
ShortTermInvestments
5200000
CY2024Q1 us-gaap Assets Of Disposal Group Including Discontinued Operation
AssetsOfDisposalGroupIncludingDiscontinuedOperation
0
CY2023Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation
AssetsOfDisposalGroupIncludingDiscontinuedOperation
0
CY2024Q1 us-gaap Liabilities Of Disposal Group Including Discontinued Operation
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
0
CY2023Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
0
CY2023Q1 us-gaap Inventory Write Down
InventoryWriteDown
23000
CY2024Q1 us-gaap Inventory Write Down
InventoryWriteDown
0
CY2024Q1 rkda Inventory Raw Materials Current And Non Current
InventoryRawMaterialsCurrentAndNonCurrent
502000
CY2023Q4 rkda Inventory Raw Materials Current And Non Current
InventoryRawMaterialsCurrentAndNonCurrent
484000
CY2024Q1 rkda Inventory Goods In Process Current And Non Current
InventoryGoodsInProcessCurrentAndNonCurrent
44000
CY2023Q4 rkda Inventory Goods In Process Current And Non Current
InventoryGoodsInProcessCurrentAndNonCurrent
55000
CY2024Q1 rkda Inventory Finished Goods Current And Non Current
InventoryFinishedGoodsCurrentAndNonCurrent
4463000
CY2023Q4 rkda Inventory Current And Non Current Net
InventoryCurrentAndNonCurrentNet
5312000
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2790000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2893000
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2462000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2509000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
328000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
384000
CY2024Q1 us-gaap Depreciation
Depreciation
51000
CY2023Q1 us-gaap Depreciation
Depreciation
71000
CY2024Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
2000
CY2024Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
17000
CY2023Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
19000
CY2023Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
30000
CY2023Q4 us-gaap Assets Held For Sale Long Lived Fair Value Disclosure
AssetsHeldForSaleLongLivedFairValueDisclosure
51000
CY2024Q1 rkda Disposal Group Including Discontinued Operation Impairment Of Property And Equipment
DisposalGroupIncludingDiscontinuedOperationImpairmentOfPropertyAndEquipment
36000
CY2024Q1 us-gaap Assets Held For Sale Long Lived Fair Value Disclosure
AssetsHeldForSaleLongLivedFairValueDisclosure
15000
CY2024Q1 rkda Debt And Equity Securities Amortized Cost Basis
DebtAndEquitySecuritiesAmortizedCostBasis
6853000
CY2024Q1 rkda Debt And Equity Securities Accumulated Gross Unrealized Gain Before Tax
DebtAndEquitySecuritiesAccumulatedGrossUnrealizedGainBeforeTax
161000
CY2024Q1 rkda Debt And Equity Securities Accumulated Gross Unrealized Loss Before Tax
DebtAndEquitySecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2024Q1 rkda Debt And Equity Securities
DebtAndEquitySecurities
7014000
CY2023Q4 rkda Debt And Equity Securities Amortized Cost Basis
DebtAndEquitySecuritiesAmortizedCostBasis
9948000
CY2023Q4 rkda Debt And Equity Securities Accumulated Gross Unrealized Gain Before Tax
DebtAndEquitySecuritiesAccumulatedGrossUnrealizedGainBeforeTax
101000
CY2023Q4 rkda Debt And Equity Securities Accumulated Gross Unrealized Loss Before Tax
DebtAndEquitySecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2023Q4 rkda Debt And Equity Securities
DebtAndEquitySecurities
10049000
CY2024Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
CY2024Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
7014000
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
10049000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
695000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
792000
CY2024Q1 rkda Operating Lease Assets
OperatingLeaseAssets
695000
CY2023Q4 rkda Operating Lease Assets
OperatingLeaseAssets
792000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
801000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
852000
CY2024Q1 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
Some leases (the Dallas and Davis offices, a warehouse, and a copy machine) include one or more options to renew, with renewal terms that can extend the lease term from one to six years. The exercise of lease renewal options is at the Company’s sole discretion. In January 2024, the Company exercised it's option to renew the facility lease in American Falls, Idaho for one year through December 31, 2024.
CY2024Q1 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2024Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
155000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
822000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1007000
CY2024Q1 us-gaap Lease Cost
LeaseCost
147000
CY2023Q1 us-gaap Lease Cost
LeaseCost
86000
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y1M6D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y3M18D
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.067
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.06
CY2023Q1 rkda Stock Issued During Period Shares Related To Exercise Of Warrants
StockIssuedDuringPeriodSharesRelatedToExerciseOfWarrants
-482647
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
341957
CY2024Q1 rkda Stock Issued During Period Shares Related To Exercise Of Warrants
StockIssuedDuringPeriodSharesRelatedToExerciseOfWarrants
-75000
CY2024Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
266957
CY2024Q1 rkda Number Of Equity Incentive Plans
NumberOfEquityIncentivePlans
2
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
80030
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
85.30
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2024Q1 rkda Share Based Compensation Arrangement By Share Based Payment Award Grants Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsOutstandingIntrinsicValue
0
CY2024Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1561
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
15.13
CY2024Q1 rkda Share Based Compensation Arrangement By Share Based Payment Award Forfeiture Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureOutstandingIntrinsicValue
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1787
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
70.99
CY2024Q1 rkda Share Based Compensation Arrangement By Share Based Payment Award Expired Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiredOutstandingIntrinsicValue
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
76682
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
87.06
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
72526
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
90.78
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
42084
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
138.73
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
495000
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P0Y9M18D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
138000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
212000
CY2024Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2024Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2024Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2024Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1833591
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1820494
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-058563-index-headers.html Edgar Link pending
0000950170-24-058563-index.html Edgar Link pending
0000950170-24-058563.txt Edgar Link pending
0000950170-24-058563-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rkda-20240331.htm Edgar Link pending
rkda-20240331.xsd Edgar Link pending
rkda-ex31_1.htm Edgar Link pending
rkda-ex31_2.htm Edgar Link pending
rkda-ex32_1.htm Edgar Link pending
rkda-ex32_2.htm Edgar Link pending
Show.js Edgar Link pending
rkda-20240331_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable